Ovid Therapeutics (OVID) Net Cash Flow (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Net Cash Flow came in at $81.0 million in Q1 2026, up 1668.89% YoY from $4.6 million in Q1 2025, and up 1216.62% on a QoQ basis from -$7.3 million in Q4 2025.
Ovid Therapeutics (OVID) Net Cash Flow (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Net Cash Flow data on file, last reported at $81.0 million in Q1 2026.
- Quarterly Net Cash Flow rose 1668.89% year-over-year to $81.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.3 million (up 860.26% YoY) and the FY2025 annual result came in at -$12.9 million, down 1649.59% from the prior year.
- Net Cash Flow grew to $81.0 million in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $81.0 million in Q1 2026 to a low of -$93.9 million in Q2 2022.
- A 5-year average of -$5.5 million and a median of -$7.3 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 349.4% — and 2026, when it soared 1668.89%.
- Tracing OVID's Net Cash Flow over 5 years: stood at -$13.4 million in 2022, then slumped by 127.01% to -$30.4 million in 2023, then surged by 137.13% to $11.3 million in 2024, then sank by 164.31% to -$7.3 million in 2025, then soared by 1216.62% to $81.0 million in 2026.
- The last three Net Cash Flow figures came in at $81.0 million (Q1 2026), -$7.3 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | 81.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.03 Mn |
| Mar 31, 2026 | 81.03 Mn |
| Dec 31, 2025 | -7.26 Mn |
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | -7.76 Mn |
| Sep 30, 2025 | -7.76 Mn |
| Jun 30, 2025 | 7.23 Mn |
| Jun 30, 2025 | 7.23 Mn |
| Mar 31, 2025 | -5.17 Mn |
| Mar 31, 2025 | -5.17 Mn |
| Dec 31, 2024 | 11.28 Mn |
| Dec 31, 2024 | 11.28 Mn |
| Sep 30, 2024 | -14.68 Mn |
| Sep 30, 2024 | -14.68 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Dec 31, 2023 | -30.39 Mn |
| Dec 31, 2023 | -30.39 Mn |